Can clinicians distinguish cannabis-induced psychosis from schizophrenia?
A study of 307 inpatients found that cannabis-induced psychosis patients had fewer negative symptoms, fewer auditory hallucinations, and more mania symptoms than schizophrenia patients, though no unique clinical pattern was identified; both cannabis-using groups had earlier first hospitalizations.
Quick Facts
What This Study Found
Cannabis-induced psychosis (CIP) patients had lower negative PANSS scores (12.9 vs 17.2, p<0.001), fewer auditory hallucinations (60.3% vs 78.9%), and more mania (26.1% vs 12.3%, p<0.001) compared to schizophrenia with cannabis. Few differences existed between schizophrenia groups regardless of cannabis use. Both cannabis-using groups had earlier age of first psychotic admission (CIP: 26.1, SZ+CB: 25.3 vs SZ: 34.2, p<0.001).
Key Numbers
69 CIP, 57 SZ+CB, 181 SZ; CIP negative PANSS: 12.9 vs SZ: 17.2; auditory hallucinations: 60.3% vs 78.9%; mania: 26.1% vs 12.3%; age first admission: CIP 26.1, SZ+CB 25.3, SZ 34.2
How They Did This
Cross-sectional comparison of three inpatient groups: cannabis-induced psychosis (n=69), schizophrenia with cannabis (n=57), and schizophrenia without cannabis (n=181). The PRISM-IV scale differentiated induced psychosis. Symptoms assessed with PANSS.
Why This Research Matters
Distinguishing cannabis-induced psychosis from primary schizophrenia has treatment implications. While no pathognomonic clinical pattern was found, the symptom profile differences (fewer negatives, more mania) may help clinicians consider CIP as a diagnosis.
The Bigger Picture
The finding that cannabis-using groups had earlier first hospitalizations (by nearly a decade) strengthens the case that cannabis precipitates psychosis earlier in vulnerable individuals. The lack of clinical differences between schizophrenia groups (with and without cannabis) suggests that once schizophrenia develops, cannabis history may not alter the clinical picture.
What This Study Doesn't Tell Us
Cross-sectional design. Single-site study. Retrospective diagnosis of cannabis-induced vs primary psychosis is inherently challenging. Different group sizes may affect statistical power.
Questions This Raises
- ?Does cannabis-induced psychosis progress to schizophrenia in some patients, and if so, does the symptom profile shift?
- ?Could the mania component in CIP be a distinguishing feature for clinical decision-making?
- ?Would biomarkers help differentiate CIP from schizophrenia?
Trust & Context
- Key Stat:
- First admission ~8 years earlier in cannabis groups
- Evidence Grade:
- Moderately sized clinical comparison using validated diagnostic instruments, but cross-sectional and single-site.
- Study Age:
- Published in 2021; the distinction between cannabis-induced and primary psychosis remains clinically challenging.
- Original Title:
- Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use.
- Published In:
- Adicciones, 33(2), 95-108 (2021)
- Authors:
- Rentero, David, Arias, Francisco, Sánchez-Romero, Sergio, Rubio, Gabriel, Rodríguez-Jiménez, Roberto
- Database ID:
- RTHC-03454
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Is cannabis-induced psychosis different from schizophrenia?
This study found CIP patients had fewer negative symptoms, fewer auditory hallucinations, and more manic features. However, no single clinical pattern was unique to CIP, making diagnosis challenging.
Does cannabis make psychosis happen sooner?
Both cannabis-using groups (whether CIP or schizophrenia with cannabis) were first hospitalized nearly a decade earlier than schizophrenia patients without cannabis use, supporting the idea that cannabis precipitates psychosis in vulnerable individuals.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-03454APA
Rentero, David; Arias, Francisco; Sánchez-Romero, Sergio; Rubio, Gabriel; Rodríguez-Jiménez, Roberto. (2021). Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use.. Adicciones, 33(2), 95-108. https://doi.org/10.20882/adicciones.1251
MLA
Rentero, David, et al. "Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use.." Adicciones, 2021. https://doi.org/10.20882/adicciones.1251
RethinkTHC
RethinkTHC Research Database. "Cannabis-induced psychosis: clinical characteristics and its..." RTHC-03454. Retrieved from https://rethinkthc.com/research/rentero-2021-cannabisinduced-psychosis-clinical-characteristics
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.